MA5-15629

antibody from Invitrogen Antibodies

Targeting: CDK1 CDC2, CDC28A

Western blot (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-15629

Provider

Invitrogen Antibodies

Product name

CDK1 Monoclonal Antibody (8C5A6)

Antibody type

Monoclonal

Antigen

Purifed from natural sources

Description

MA5-15629 targets CDC2 in IHC and WB applications and shows reactivity with Human samples.

Antibody clone number

8C5A6

Concentration

Conc. Not Determined

References

Submitted references

Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair.

Malacrida A, Cavaletti G, Miloso M
International journal of molecular sciences 2021 Dec 25;23(1)

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of CDC2 using CDC2 monoclonal antibody (Product # MA5-15629) in Jurkat (1) cell lysate.

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical analysis of paraffin-embedded human lung cancer (A) and esophageal cancer (B) using CDC2 monoclonal antibody (Product # MA5-15629) followed with DAB staining.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 4 Western blot analysis of P-CDK1 and PLK1 in EGI-1 cells treated with Rig. ( A ) Representative images of P-CDK1, PLK1 and actin after treatment with different concentrations of 100 nM Rig for 24 and 48 h. ( B ) The graph represents the quantification of P-CDK1 Western blot, normalized to actin. ( C ) The graph represents the quantification of PLK1 western blot, normalized to actin. All the graphs are represented as the mean percentage +- SD of at least three independent experiments and are compared to untreated controls arbitrarily set to 100%. * p < 0.05 vs. CTRL.